NEUROCRINE BIOSCIENCES INC Assets, Fair Value Disclosure
NEUROCRINE BIOSCIENCES INC (NBIX) had Assets, Fair Value Disclosure of $629.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes
us-gaap:AssetsFairValueDisclosure · last filed 2026-07-31
- 2026-06-30: Assets, Fair Value Disclosure $629.00M.
- 2026-03-31: Assets, Fair Value Disclosure $2.79B.
- 2025-12-31: Assets, Fair Value Disclosure $2.66B.
- 2024-12-31: Assets, Fair Value Disclosure $1.94B.
| Period end | Assets, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $629.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $2.79B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $2.66B 10-Q · filed 2026-07-31 |
| 2024-12-31 | $1.94B 10-K · filed 2026-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |